Cognitive Evaluation in Patients with Vascular Cognitive Impairment
- 25 Downloads
Cognitive evaluation in patients with vascular cognitive impairment differs in some aspects from those of other neurodegenerative patients with dementia. Appropriate and sensitive evaluation tools should be used to assess the cognitive function, as there are differences in the cognitive domains initially affected by the disease. In addition, some patients with vascular cognitive impairment have accompanying physical disabilities, such as unilateral paralysis or a visual field defect, so it is necessary for the examiner to check carefully whether the test results are purely due to a decline in cognitive function or due to a physical impairment. In this chapter, we will discuss the various cognitive function assessment methods currently in use for patients with vascular cognitive impairment and discuss their advantages and disadvantages. In addition, we will briefly discuss the neuropsychological construct in patients with vascular cognitive impairment and the characteristics of longitudinal cognitive changes.
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (No.2017R1C1B5018132).
- 1.Sachdev PS, Lo JW, Crawford JD, et al. STROKOG (stroke and cognition consortium): an international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimers Dement (Amst). 2017;7:11–23.Google Scholar
- 7.American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association, 2013.Google Scholar
- 14.Pendlebury ST, Mariz J, Bull L, et al. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43(2):464–9.PubMedCrossRefGoogle Scholar
- 20.Imai Y, Hasegawa K. The revised Hasegawa’s Dementia Scale (HDS-R): evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatr. 1994;4:20–4.Google Scholar
- 30.Barbay M, Taillia H, Nedelec-Ciceri C, et al. Prevalence of poststroke neurocognitive disorders using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG criteria (vascular behavioral and cognitive disorders), and optimized criteria of cognitive deficit. Stroke. 2018;49(5):1141–7.PubMedCrossRefGoogle Scholar
- 35.Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875–84.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014;13(12):1177–85.PubMedPubMedCentralCrossRefGoogle Scholar